bi-4SCAR GD2/CD70 / SZGIMI - LARVOL DELTA

GD2/CD70 Bi-specific CAR-T Cell Therapy (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Jun 2026 ➔ Dec 2030 | Trial primary completion date: Dec 2025 ➔ Dec 2029

Trial completion date • Trial primary completion date • Oncology • CD70